Clostridioides Difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population

Overview

Journal Infect Dis Clin North Am

Specialty Infectious Diseases

Date 2019 Apr 22

PMID 31005136

Citations 6

Authors

Elizabeth Ann Misch

Nasia Safdar

Affiliations

Soon will be listed here.

Abstract

Clostridioides difficile infection (CDI) is common in the stem cell transplant (SCT) and hematologic malignancy (HM) population and mostly occurs in the early posttransplant period. Treatment of CDI in SCT/HM is the same as for the general population, with the exception that fecal microbiota transplant (FMT) has not been widely adopted because of safety concerns. Several case reports, small series, and retrospective studies have shown that FMT is effective and safe. A randomized controlled trial of FMT for prophylaxis of CDI in SCT patients is underway. In addition, an abundance of novel therapeutics for CDI is currently in development.

Citing Articles

Effectiveness of oral vancomycin as prophylaxis against infection in hematopoietic stem cell transplant patients.

Reitmeyer K, Rana B, Awad D, Huang E, Park J, Yassin A Antimicrob Steward Healthc Epidemiol. 2025; 4(1):e107.

PMID: 39823126 PMC: 11736458. DOI: 10.1017/ash.2024.90.

Evaluation of Primary Oral Vancomycin Prophylaxis Against Infection During Autologous Stem Cell Transplantation.

Williams M, Atienza S, Franzen E, Rathod H, Mejaki B, Graff J Open Forum Infect Dis. 2024; 11(11):ofae622.

PMID: 39498172 PMC: 11532790. DOI: 10.1093/ofid/ofae622.

Effects of Staphylococcus aureus on stem cells and potential targeted treatment of inflammatory disorders.

Liu Z, Liu G, Lin Z, Chen Y, Chen P, Hu Y Stem Cell Res Ther. 2024; 15(1):187.

PMID: 38937829 PMC: 11210046. DOI: 10.1186/s13287-024-03781-6.

A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States.

Eeuwijk J, Ferreira G, Yarzabal J, Robert-Du Ry van Beest Holle M Infect Dis Ther. 2024; 13(2):273-298.

PMID: 38349594 PMC: 10904710. DOI: 10.1007/s40121-024-00919-0.

Challenges and Opportunities in Antimicrobial Stewardship among Hematopoietic Stem Cell Transplant and Oncology Patients.

Majumdar A, Shah M, Park J, Narayanan N, Kaye K, Bhatt P Antibiotics (Basel). 2023; 12(3).

PMID: 36978459 PMC: 10044884. DOI: 10.3390/antibiotics12030592.

References

Gerding D, Meyer T, Lee C, Cohen S, Murthy U, Poirier A . Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015; 313(17):1719-27. DOI: 10.1001/jama.2015.3725. View

Cornely O, Crook D, Esposito R, Poirier A, Somero M, Weiss K . Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012; 12(4):281-9. DOI: 10.1016/S1473-3099(11)70374-7. View

Kamboj M, Xiao K, Kaltsas A, Huang Y, Sun J, Chung D . Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. Biol Blood Marrow Transplant. 2014; 20(10):1626-33. PMC: 4852556. DOI: 10.1016/j.bbmt.2014.06.025. View

Guddati A, Kumar G, Ahmed S, Ali M, Kumar N, Hari P . Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. Int J Hematol. 2014; 99(6):758-65. DOI: 10.1007/s12185-014-1577-z. View

Satlin M, Vardhana S, Soave R, Shore T, Mark T, Jacobs S . Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(10):1808-14. PMC: 4568152. DOI: 10.1016/j.bbmt.2015.06.017. View

Arango J, Restrepo A, Schneider D, Callander N, Ochoa-Bayona J, Restrepo M . Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006; 37(5):517-21. DOI: 10.1038/sj.bmt.1705269. View

Willems L, Porcher R, Lafaurie M, Casin I, Robin M, Xhaard A . Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012; 18(8):1295-301. DOI: 10.1016/j.bbmt.2012.02.010. View

Bartlett J, MOON N, Chang T, Taylor N, Onderdonk A . Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978; 75(5):778-82. View

DeFilipp Z, Hohmann E, Jenq R, Chen Y . Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018; 25(1):e17-e22. DOI: 10.1016/j.bbmt.2018.10.022. View

10.

Khan M, Dirweesh A, Khurshid T, Siddiqui W . Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018; 30(11):1309-1317. DOI: 10.1097/MEG.0000000000001243. View

11.

Yoon Y, Kim M, Sohn J, Kim H, Choi Y, Kim J . Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy. Support Care Cancer. 2014; 22(8):2039-48. DOI: 10.1007/s00520-014-2174-7. View

12.

Debast S, Bauer M, Kuijper E . European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2013; 20 Suppl 2:1-26. DOI: 10.1111/1469-0691.12418. View

13.

Leav B, Blair B, Leney M, Knauber M, Reilly C, Lowy I . Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2009; 28(4):965-9. DOI: 10.1016/j.vaccine.2009.10.144. View

14.

Mullane K, Winston D, Nooka A, Morris M, Stiff P, Dugan M . A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2018; 68(2):196-203. PMC: 6321849. DOI: 10.1093/cid/ciy484. View

15.

Wilcox M, Planche T, Fang F, Gilligan P . What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?. J Clin Microbiol. 2010; 48(12):4347-53. PMC: 3008464. DOI: 10.1128/JCM.02028-10. View

16.

Young J, Logan B, Wu J, Wingard J, Weisdorf D, Mudrick C . Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Transplant. 2015; 22(2):359-370. PMC: 4716871. DOI: 10.1016/j.bbmt.2015.09.013. View

17.

Tenover F, Novak-Weekley S, Woods C, Peterson L, Davis T, Schreckenberger P . Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010; 48(10):3719-24. PMC: 2953097. DOI: 10.1128/JCM.00427-10. View

18.

Ganetsky A, Han J, Hughes M, Babushok D, Frey N, Gill S . Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2018; 68(12):2003-2009. PMC: 6541731. DOI: 10.1093/cid/ciy822. View

19.

Gerding D, Sambol S, Johnson S . Non-toxigenic (Formerly Clostridium) for Prevention of Infection: From Bench to Bedside Back to Bench and Back to Bedside. Front Microbiol. 2018; 9:1700. PMC: 6070627. DOI: 10.3389/fmicb.2018.01700. View

20.

Peled J, Hanash A, Jenq R . Role of the intestinal mucosa in acute gastrointestinal GVHD. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):119-127. PMC: 5575743. DOI: 10.1182/asheducation-2016.1.119. View